You are here
Articles
Posted on Wednesday, April 17, 2013 - 4:13pm
Charles A. Schiffer, MD1 | October 12, 2012
Posted on Wednesday, April 17, 2013 - 4:01pm
Dave Levitan | April 12, 2013
Chronic myeloid leukemia (CML) patients treated with nilotinib(Drug information on nilotinib) had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib(Drug...
Posted on Wednesday, April 17, 2013 - 3:21pm
Dave Levitan | April 16, 2013
A study of patients with chronic myeloid leukemia (CML) treated with imatinib found that chronic fatigue is the major factor that limits health-related quality of life (HRQOL).
Posted on Wednesday, April 17, 2013 - 3:19pm
By Leah Lawrence | April 15, 2013
A majority of patients on imatinib(Drug information on imatinib) for treatment of gastrointestinal stromal tumor (GIST) or chronic myelogenous leukemia (CML) had low or absent levels of...
Posted on Thursday, April 11, 2013 - 12:05pm
S Mustjoki1, K Auvinen2,10, A Kreutzman1,10, P Rousselot3, S Hernesniemi1, T Melo4, A-M Lahesmaa-Korpinen5, S Hautaniemi5, S Bouchet6, M Molimard6, R Smykla7, F Y Lee7, J Vakkila1, S Jalkanen2,8, M Salmi2,9 and K...
Posted on Friday, April 5, 2013 - 4:24pm
Pratap Neelakantan1, Gareth Gerrard1, Claire Lucas2, Dragana Milojkovic1, Philippa May1, Lihui Wang2, Christos Paliompeis1, Marco Bua1, Alistair Reid1, Katayoun Rezvani1, Stephen O'Brien3, Richard Clark2, John Goldman1...
Posted on Sunday, March 31, 2013 - 7:45pm
Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML
Published Online: Thursday, March 28, 2013
Although it is now standard practice to utilize the second-...
Posted on Wednesday, March 27, 2013 - 1:30am
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
Massimo Breccia, Giuliana Alimena.
Posted on Wednesday, March 27, 2013 - 1:12am
Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus1, Giuseppe Saglio2,...
Posted on Saturday, March 23, 2013 - 12:00pm
21 March 2013EMA/CHMP/178415/2013 Committee for Medicinal Products for Human Use (CHMP)
Summary of opinion1 (initial authorisation)
Iclusig
Ponatinib
On 21 March 2013, the Committee for Medicinal...
Posted on Friday, March 15, 2013 - 6:59pm
Is going for cure in chronic myeloid leukemia possible and justifiable?
Posted on Friday, March 15, 2013 - 4:59pm
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
Posted on Thursday, March 14, 2013 - 11:28am
CML Stem Cell Burden at Diagnosis Associated With Treatment Outcomes
By Dave Levitan
March 11, 2013
Laboratory studies have suggested that chronic myeloid leukemia (CML) stem cells are resistant to...
Posted on Wednesday, March 13, 2013 - 1:12pm
Oncology Enters Era of Genomics: Sledge Calls for Overhaul of Clinical Trials System
Anita T. Shaffer
Posted on Sunday, March 10, 2013 - 3:11pm
Definitions, methodological and statistical issues for phase 3 clinical trials in
chronic myeloid leukemia: a proposal by the European LeukemiaNet
Joelle Guilhot,1 Michele Baccarani,2 Richard E. Clark,3...
- ‹ previous
- 15 of 33
- next ›